Summary We used RNAase protection and restriction fragment length polymorphism assays to detect activating mutations of c-src in a spectrum of human tumours. No mutations were detected at codons 98, 381, 444, and 530. We conclude that mutational activation is not the mechanism of enhancement of pp60C.srcspecific kinase activity found in a number of human cancer types.
The src proto-oncogene (c-src) is the cellular homologue of the transforming gene of the Rous sarcoma virus (RSV). Both genes encode Mr 60,000 phosphoproteins (pp6O) which are membrane bound and have tyrosine-specific protein kinase activity (Collett & Erikson, 1978; Hunter & Sefton, 1980; Levinson et al., 1980) . Comparison of the sequence of v-src from a number of RSV strains, with the cellular c-src gene, has shown that the transforming proteins contain a number of common amino acid substitutions as well as deletions of the terminal nineteen amino acids (summarised in Hunter, 1987) . Demonstration that a single point mutation is capable of activating the oncogenic properties of pp60C-src has been obtained from in vitro mutagenesis studies and analysis of c-src transformation-competent mutants (Kmiecik & Shalloway, 1987; Piwnica-Worms et al., 1987; Cartwright et al., 1987; Levy et al., 1986) . There is considerable evidence that TYR 527 is a negative regulator of kinase activity of pp6Oc-src and its deletion in v-src contributes to the elevated kinase activity of the viral protein. Substitution of TYR 527 with amino acid residues which cannot be phosphorylated also enhances the specific kinase activity of the molecule and activates its transforming properties. Additional single point mutations which activate the transforming ability of chicken pp60csrc include amino acid substitutions in the kinase domain (THR 338, GLU 378, ILE 441) and mutations in the amino terminus modulation domain, particularly at ARG 95. All of the activating mutations of pp60csrc result in an increase in the specific kinase activity of the molecule (Hunter, 1987). pp60c-src tyrosyl kinase activity has been shown to be elevated in a number of human cancers including colon cancer, neuroblastoma, breast cancer and sarcomas (Jacobs & Rubsamen, 1983; Bolen et al., 1985; Barnekow et al., 1987; Bolen et al., 1987; Cartwright et al., 1989) . For example, from two-thirds to all of colon cancers tested have been reported to have markedly elevated levels of pp60c-src kinase activity (Bolen et al., 1987; Cartwright et al., 1989 (Gibbs et al., 1985) encoding amino acids 452-532 (Figure 1, probe D) . To test the ability of the RNAase protection assay to detect single base mismatches at codon 530, we constructed a T to A mutation at the second base of that codon using oligonucleotide-directed in vitro mutagenesis (Kunkel, 1985) and cloned the mutated fragment into a SP65-based vector. Using in vitro transcription we generated sense strand RNA which was hybridised to a radioisotopically-labelled anti-sense RNA probe. The hybrid was then subjected to the RNAase cleavage assay (described in Figure 2 ). After hybridisation to the mutated RNA and digestion with RNAase, the 317 nucleotide probe was cleaved into the predicted fragments of 282 and 35 nucleotides, indicating that the conditions used in this assay could detect a single base mismatch at codon 530 (Figure 2a sensitivity of other mutation assays using RFLP analysis of be detected in the PCR amplified products .
We then utilised the RNAase protection assay to detect mutations at and around amino acids 98, 381 and 444, using the RNA probes described in Figure 1 . Fifty-five tumours (including 22 colon tumours, nine brain cancers, 11 other solid tumours, 13 lymphomas and leukaemias) were analysed ,. Lt_ _ 1A_ -_ A+Aw_ gAA_ A _ witn eacn probe ana in no instance was a mutation detected (Figure 4) .
In summary, we have been unable to detect activating mutations of pp6oC-src at the carboxy terminal regulatory site as well as a number of other relevant sites in the kinase domain and amino terminus in a spectrum of human cancers, including those cell types in which the vast majority of tumours have elevated pp6Oc-c kinase activity (e.g. colon cancers). The RNAase protection assay we used employs anti-sense RNA probes that will detect most mutations with the exception of G: U mismatches (Borer et al., 1975 formamide, 0.4M NaCl, 1 mM EDTA, and 40 mM Pipes, pH 6.7. The solution was heated to 85°C and then incubated at 56°C for 16 h. Following hybridisation, the reaction mixture was added to 300 Ll of digestion buffer (300 mm NaCl, 5 mM EDTA, 10mM Tris-HCl, pH 7.5) containing 20 jAg ml-' of RNAase A. Following incubation at 37'C for 1 h, samples were extracted with phenol/chloroform and ethanol precipitated with 10iLg tRNA. The precipitated RNA was resuspended in 10 jil of loading buffer (97% deionised formamide, 0.1% NaDod So4, 10mM Tris-HCI, pH 7.0) heated at 85°C for 3 min, and placed immediately at 4°C. Samples were subjected to electrophoresis in an 8% acrylamide/ 7 M urea vertical gel 43 cm in length. The gel was dried and exposed to X-ray film at -70C. a, Hybridisation of anti-sense probe to RNA containing codon 530 mutation (lane 1) and normal cellular RNA (lane 2). Following RNAase digestion the probe that hybridised to mutated RNA is cleaved at the site of the mismatch. b, RNAase assay of normal spleen (lane 1), B-cell lymphomas (lanes 2-13), myeloid leukaemia (lanes 14-16), small cell cancer of lung (lane 17). M-MspI digested PBR 322 DNA marker; P -undigested probe. c, RNAase protection assay of a series of colon carcinomas (lanes 1-10) . Markers are Hae III digested OX 174 and MspI digested PBR 322 DNA. There are a number of alternative explanations for the elevated pp60csrc kinase levels found in some cancers. First, activating mutations other than those we tested for, may be present in these cancers. For example, a mutation at amino acid 338 is present in all strains of RSV. We have had difficulty in establishing reproducible RNAase protection assays for this region of the c-src gene. Nevertheless, we have tested all of the other common mutation sites and have obtained negative results. Second, a transformation-related protein, similar to polyoma middle T antigen, may interact with TYR 530 and prevent its phosphorylation (Courtneidge & Smith, 1983) . Activating endogenous cellular proteins, similar to viral middle T antigen, have not yet been identified. Third, and more likely, tumours with high pp6cC-src activity may represent the clonal expansion of an undifferentiated cell type with normally high pp60C-srC activity.
Colonic epithelial cells at a specific stage in development, e.g. when they are actively dividing in an undifferentiated compartment, may normally possess high levels of pp6Oc-src activity. It is of interest that colonic stem cells located at the base of the colonic crypt have markedly elevated levels of proteins phosphorylated on tyrosine residues as compared to more mature epithelial cells at the top of the crypt (Burgess et al., 1989) . Additional evidence supporting a relationship between pp6OC-src activity and the state of differentiation of the colonic epithelium is demonstrated by experiments in which butyrate-induced differentiation of human colon carcinoma cell lines was shown to down regulate pp60cs7c kinase activity (Foss et al., 1989) .
